CLSD
NASDAQClearside Biomedical Inc.
News · 26 weeks120%
2025-12-142026-06-07
Mix090d
No activity.
Latest news
25 items- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form POS AM filed by Clearside Biomedical Inc.POS AM - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form S-8 POS filed by Clearside Biomedical Inc.S-8 POS - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form POS AM filed by Clearside Biomedical Inc.POS AM - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form 8-K filed by Clearside Biomedical Inc.8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form 25 filed by Clearside Biomedical Inc.25 - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECClearside Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- PRClearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process- Intended to Maximize Stakeholder Value Through Structured Process - - Validated SCS Microinjector® Delivery Platform Anchored by Commercial Product and Five Suprachoroidal Licensing Collaborations with Future Royalty Revenue Potential - - CLS-AX TKI Program Includes Phase 3-Ready Asset in Wet AMD and Path for Phase 2b/3 Trial in Diabetic Retinopathy - - IND-Ready Programs Targeting Geographic Atrophy and Diabetic Macula Edema - ALPHARETTA, Ga., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (
- SECSEC Form 10-Q filed by Clearside Biomedical Inc.10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECClearside Biomedical Inc. filed SEC Form 8-K: Other Events8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECClearside Biomedical Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECClearside Biomedical Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECClearside Biomedical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECClearside Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Submission of Matters to a Vote of Security Holders8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECClearside Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update8-K - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form 10-Q filed by Clearside Biomedical Inc.10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)
- SECSEC Form DEF 14A filed by Clearside Biomedical Inc.DEF 14A - Clearside Biomedical, Inc. (0001539029) (Filer)
CLSD FAQ
7 questionsWhat does Clearside Biomedical Inc. do?
Clearside Biomedical, Inc., a biopharmaceutical company, engages in the developing and delivering treatments that restore and preserve vision for people with serious eye diseases. Its product includes CLS-AX, an axitinib for suprachoroidal injection which is in Phase 1/2a clinical trial. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Where does CLSD stock trade?
Clearside Biomedical Inc. (CLSD) is listed on NASDAQ.What sector and industry is CLSD in?
Clearside Biomedical Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Clearside Biomedical Inc. go public?
Clearside Biomedical Inc. (CLSD) completed its IPO in 2016.What are analysts saying about CLSD?
Clearside Biomedical Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Hold with a $200.00 price target on 2025-07-18. Recent price targets range from $200.00 to $1000.00.What companies are similar to CLSD?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CLSD side-by-side with any of them on Quantisnow.How can I track CLSD on Quantisnow?
Quantisnow aggregates Clearside Biomedical Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CLSD to receive live email and push alerts on every new disclosure.